KR20130022733A - Composition for treatment of pancreatic cancer and beauty expenses composition comprising extract of coptidis rhizoma - Google Patents

Abstract

PURPOSE: A composition and a cosmetic composition containing a Coptidis rhizoma extract are provided to suppress the growth of pancreatic cancer cells and to induce pancreatic cancer cell apoptosis. CONSTITUTION: A cosmetic composition for treating pancreatic cancer contains an ethanol extract of Coptidis rhizoma as an active ingredient. The extract is prepared at 50 deg. C for 24 hours and is dried and concentrated at a reduced pressure at 45 deg. C. The composition contains a pharmaceutically acceptable carrier or diluent. The pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cellular viability

Description

Composition for Treatment of Pancreatic Cancer and Beauty Expenses Composition Comprising Extract of Coptidis Rhizoma}

The present invention relates to a novel use of the cheonyan lotus extract. Specifically, the present invention relates to a therapeutic composition and cosmetic composition containing the cheonyan lotus extract as an active ingredient exhibiting excellent preventive or therapeutic efficacy against pancreatic cancer.

Among the major diseases of modern people, researches on the treatment and diagnosis of cancer are relatively active, mainly in lung cancer, liver cancer, gastric cancer, and the like. However, studies on esophageal cancer, colorectal cancer, and pancreatic cancer with low incidence are relatively low.

The pancreas produces insulin, which helps the body convert glucose into energy, and enzymes that help the body digest food. Pancreatic cancer is a malignant growth of the pancreas, mainly occurring in cells of the pancreatic duct. The disease is the ninth most common form of cancer, but it is the fourth and fifth most common cause of cancer deaths in men and women, respectively. Pancreatic cancer has a five-year survival rate of less than 3%, most of which is always fatal. Pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) in the pancreatic cancer, which accounts for more than 90% of pancreatic cancer generally refers to pancreatic adenocarcinoma. Pancreatic adenocarcinoma is also called pancreatic adenocarcinoma, pancreatic adenocarcinoma, or pancreatic adenocarcinoma.

 Like many other malignant diseases, pancreatic cancer arises from the accumulation of acquired mutations. Multiple genetic and epigenetic changes, including activation of protocogenes, inactivation of tumor suppressor genes, and malformations of maintenance genes, may result in the development, sustained growth, and metastasis of pancreatic cancer. Related to Accumulated mutations in such genes are known to occur within predictable time during the "PanINs" (Pancreatic Intraepithelial Neoplsia) phase (Hruban et al. (2000) Clin Cancer Res 6: 2969-2972; Kern (2002) Cancer Biol Therapy 1: 607-613; Li et al. (2004) Lancet 363: 1049-1057). K-ras mutations occur about half of PanIN-1. The PanIN-2 stage is represented by additional changes and increases in the rate of K-ras mutations, and the appearance of multiple p16 malformations, and p53 protein family expression, which may indicate the presence of p53 mutations, is sometimes seen in more advanced PanINs. Loss of the tumor suppressor genes, TP53, DPC4 and BRCA2, appears to occur late in the development of pancreatic tumorigenesis, PanIN-3. Specifically, more than 85% of pancreatic adenocarcinomas have K-ras gene point mutations activated in pancreatic cancer development (Li et al. (2004) Lancet 363: 1049-1057; Xiong (2004) Cancer Chem Pharm 54: S69-77). K-ras mutations induce constitutive activation of Ras-Raf-MEK-ERK, an intracellular signaling pathway that induces cell proliferation and confers transgene properties on cells containing point mutations. Cause. Ras mutations are not associated with tumor stage or prognosis, and indicate that the K-ras oncogene may be involved in the onset of carcinogenesis but not in the likelihood or promotion of human pancreatic cancer. One of the major downstream targets of the ras family is phosphoinositol 3 kinase (PI3K). Activation of PI3K is associated with pancreatic cancer resistance to apotosis induced by chemotherapy or molecular drug targeting agents.

Pancreatic adenocarcinoma is one of the most deadly human malignancies with more than 30,000 deaths annually in the United States alone. At diagnosis these cancers are found in a state where only 10% to 15% can be excised due to the presence of locally advanced disease or distant metastasis. Recently, the most common treatment strategy for advanced pancreatic cancer is gemcitabine, a 2'-deoxycytidine nucleoside analogue for intravenous administration that can induce apoptosis of human pancreatic cancer cells and inhibit tumor growth and progression. It is a treatment by. However, despite the best medical or surgical treatment, the results of treatment of patients with pancreatic adenocarcinoma are terrible, and as a group, the median survival of patients with this disease is 21 months or less. Thus, there is a need for clear, new and efficient treatment strategies to combat this deadly disease. As such, pancreatic cancer is a major health issue in developed countries and has a very poor prognosis (Faint et al. (2004) Datamonitor DMHC2045; Garcea et al. (2005) Pancreatology 5: 514-529; Kern et al. (2002). ) Cancer Biol Therapy 1: 607-613; Laheru and Jaffee (2005) Nature Rev Cancer 5: 59-467; Li et al. (2004) Lancet 363: 1049-1057). Despite excessive surgical and medical treatment, the mean life expectancy is about 15-18 months for patients with local disease and 3-6 months for patients with metastatic disease. Nearly 100% of patients with pancreatic cancer experience metastasis and die due to their unrestricted growth, which weakens metabolism, and less than 5% of patients who have not undergone resection survive a total of 5 years. Do. In addition, there is a problem that the initial diagnosis is difficult due to the non-specific initial symptoms. Currently, early detection of pancreatic cancer is still under development and not commercially available, and conventional cancer treatments have little effect on prognosis or disease outcome. Poor prognosis for pancreatic cancer is due to late manifestation, aggressive local invasion, early metastasis and insufficient response to chemotherapy.

The most common symptoms of pancreatic cancer include jaundice, abdominal pain and weight loss, and are not substantially special along with other emergence factors. Thus, diagnosing pancreatic cancer at an early stage of tumor growth is often difficult and requires a situation that includes considerable doubt and extensive diagnostic overhauls, often exploratory surgery. Endoscopic ultrasonography and computed tomography (CT) are the best noninvasive methods currently available for diagnosing pancreatic cancer. However, as well as differentiation of pancreatic cancer from lesioned pancreatitis, reliable detection of small tumors is difficult. Unfortunately, the majority of patients are currently diagnosed at a late stage where the tumor has already invaded the surrounding organs, extending outward and / or extensively metastasized (Gold et al., Crit. Rev. Oncology / Hematology, 39: 147-54 (2001). The disease is late detection is common, and early diagnosis of pancreatic cancer is rare in clinical settings.

Currently available treatment methods for pancreatic cancer do not cure the disease or reach a substantially improved survival time. Surgical resection is the only way to provide survival. However, due to tumor burden, only 10-25% of patients are targeted for 'curative resection'. In these patients undergoing resection treatment, the 5-year survival rate is still on average at around 10%.

On the other hand, Coptidis Rhizoma is the root stem of Coptis japonica, which lowers heat, removes moisture, lowers fire, detoxifies, nourishs blood, and is darkened. Soothe the boundaries, eliminate roundworms, brighten the eyes, soothe the tickles, clear the heart, soothe the stomach, thicken the intestines, harden bones, and muscle (肌肉) to have a strong and insecticidal effect.

However, nothing has been disclosed or disclosed in this document in relation to pancreatic cancer-related diseases of cheonyan lotus.

Thus, the present inventors completed the present invention by confirming that during the herbal medicine research on the cheonnyeonryun can be effectively killed pancreatic cancer cells.

It is an object of the present invention to provide a composition for treating pancreatic cancer and a cosmetic composition containing the cheonyan lotus extract as an active ingredient.

In order to achieve the above object, the present invention provides a composition for the prevention and treatment of pancreatic cancer containing Coptidis Rhizoma ethanol extract as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing pancreatic cancer containing ethanol extract of Coptidis Rhizoma containing cosmetically acceptable cosmetic auxiliary additives as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for the prevention and treatment of pancreatic cancer containing Coptidis Rhizoma ethanol extract as an active ingredient. The composition of the present invention contains the extract of cheonnyeo as active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.

In the composition for preventing and treating pancreatic cancer of the present invention, the ethanol extract is preferably extracted for 24 hours at 50 ℃, wherein the ethanol extract is more preferably dried and concentrated at 45 ℃ reduced pressure conditions, the ethanol is Most preferred is 95%.

In addition, in the composition for preventing and treating pancreatic cancer of the present invention, the pancreatic cancer is preferably pancreatic ductal adenocarcinoma.

The cheonnwang lotus extract of the present invention is possible in any part of cheonnyeon lotus, but is preferably extracted from the root stem. The extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane. Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.

Specifically, 1 to 5 times, preferably 3 times, 95% ethanol is added to the dried or powdered cheonyan lotus and 10 to 100 hours, preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C. To 40 hours, more preferably, 24 hours after extraction can be filtered to prepare the ethanol extract of the cheonyan lotus. Preferably, the filtrate obtained by filtering the extract may be concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.

The "pharmaceutically acceptable carrier" is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.

The composition for treating pancreatic cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .

Formulations for medicating the extract of Cheonhwang lotus of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and liquid preparations for oral use include suspensions, solvents, emulsions, and syrups. In addition to liquids and paraffins, various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.

In addition, the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Coptidis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set, Uncaria Uncus, Ponciri Fructus, Ginseng (Gingseng), Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Chrysanthemi Flos, Windbreak (Ledebouriellae Radix), Ginger (Zingiberudris Rhizoma) ), Natrii sulfas, Zizyphi Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Mint (Menthae Herba), Herbal Medicine (Dioscoreae Rhizoma), Poly (Polyporus), Polygoni multiflori Radix, Allii tuberosi Semen, Cassiae Semen, Goji (Lycii Fructus), Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Anemarrhenae Rhizoma, Safflower, Carthami Flos (Astragali Radix), Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Kelis (Fossilia ossis Mastodi), Lycii radicis Cortex, Achyranthis Radix Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Malt (Hordei Fructus germinatus), Cuscutae Semen, Morindae Radix, Pini koraiensis Radix, etc. Can be.

The composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like. In addition to water, liquid, and paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Specifically, preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. In addition, calcium or vitamin D ₃ may be added to enhance the efficacy of the treatment. Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

The formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination. The invention also includes formulations of dosage units. The formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage. Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times. The individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.

As used herein, the term "extract" refers to an active ingredient isolated from natural products. The extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.

In a specific embodiment of the present invention, the ethanol extract of Cheonhwang Lyeon killed 60.2% of Panc-1 pancreatic cancer cells at 100 μg / ml and the IC ₅₀ (half maximal inhibitory concentration) was 83.0 μg / ml. The above results demonstrate that the cheonyan lotus extract of the present invention has excellent killing activity of Panc-1 pancreatic cancer cells and further has pancreatic cancer treatment and prophylactic activity.

As used herein, the term "prevention" means any action that inhibits or delays the development of pancreatic cancer by administration of the composition.

As used herein, the term "treatment" means any action that improves or beneficially alters the symptoms of pancreatic cancer by administration of the composition.

The cheonyan lotus extract in the present invention can be used to extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol. The extracted solution can be used directly or can be concentrated and / or dried. When extracted with an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like. Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.

Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration. The post-concentration drying step includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like. If desired, a process of grinding the final dried extract may be added.

In addition, the extract can perform an additional fractionation process. Preferably, the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.

In the present invention, the term "pharmaceutically acceptable salts" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.

The pharmaceutical composition for preventing and treating pancreatic cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like. In addition, the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as. In addition, the composition may include a substance having a therapeutic activity against pancreatic cancer, used alone or previously used.

As used herein, the term "patient" refers to humans and horses, sheep, pigs, goats, camels, who have diseases caused by pancreatic cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals. By administering to the patient a composition comprising the extract of the cheonyan lotus, it is possible to effectively prevent and treat the above-mentioned pancreatic cancer. The composition of the present invention can be administered in parallel with existing pancreatic cancer therapeutics.

As used herein, the term "administration" means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered. In addition, the composition may be administered by any device in which the active agent may migrate to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration. In general, when the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day. Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.

In addition, the present invention provides a cosmetic composition for preventing pancreatic cancer containing ethanol extract of Coptidis Rhizoma containing cosmetically acceptable cosmetic auxiliary additives as an active ingredient.

The cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract. The cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.

In the present invention, the Panc-1 pancreatic cancer cells were injected with the cheonyan lotus extract of the present invention, and it was confirmed that Panc-1 cells were killed (see FIG. 1 ). Thus, it can be seen that the extract of the cheonyan lotus has a pancreatic cancer treatment effect. Thus, in the present invention, the present invention was completed by preparing a cosmetic composition for preventing pancreatic cancer, which contains the extract of cheonyan lotus as an active ingredient (see Preparation Example 2 ).

As discussed above, the extract of cheonhwangyeon of the present invention inhibits the growth of pancreatic cancer cells and induces apoptosis. Therefore, the composition for treating pancreatic cancer according to the present invention will be very effective for the treatment of pancreatic cancer patients.

1 is a result of Alamar Blue analysis to determine the effect of the introduction of the cheonnyeon lotus on the growth of pancreatic cancer cells in Panc-1 cells, which are human pancreatic cancer cells, wherein the X axis is the concentration of the extract of the cheonyan lotus, and the Y axis is the surviving human pancreatic cancer The viability of the cells is shown.

Hereinafter, the present invention will be described in more detail based on the following examples. It should be noted, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The present invention is not limited to the following examples. Will be apparent to those skilled in the art to which the present invention pertains.

Example 1 Preparation of Cheonhwang Lotus Extract

3 kg of Cheonhwang Lotus (made in China) purchased from Seoul medicinal herb was dried and ground for 5 days at the shade and room temperature. The milled lotus was immersed in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure of 45 ° C. to obtain 298 g of the total extract, which was stored at −20 ° C.

Example 2 Effect of Cheonhwang Lyeon Extract on the Growth of Pancreatic Cancer Cells

In order to examine the effect of the extract of Example 1 on the growth of pancreatic cancer cells, Panc-1 cells, which are human pancreatic cancer cells, were treated with ethanol extracts of the Cheonsul lotus for 48 hours and subjected to Alamar Blue analysis. The Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.

<2-1> Preparation and Treatment of Human Pancreatic Cancer Cell Lines

Panc-1 cells, a pancreatic cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, Panc-1 pancreatic cancer cells are DMEM (Dulbeco's Modified Eagle's) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Medium) was passaged in medium.

<2-2> Inhibition of Cell Growth in Panc-1 Pancreatic Cancer Cells

It was confirmed that the extract of Example 1 extract of Example 1 extract inhibits the growth of Panc-1 cells, which are pancreatic cancer cells. Specifically, 4.5 ± 10 ³ Panc-1 pancreatic cancer cells per well were seeded in a 96 well plate, incubated for 24 hours, and then dissolved in DMSO (dimethyl sulfoxide). When the ethanol extract was treated at concentrations of 0 to 100 μg / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50, and 100 μg / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1). After treatment with each concentration of extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of cell culture filled in each well in a 96-well plate, and the plates were incubated for 2 hours in an incubator. The plate was slowly shaken to evenly react the cells of each well, and the intensity of fluorescence was measured at 590 nm with a Fluorescence Microplate Reader (Molecular Devices Corp.) while irradiating irradiated light at a wavelength of 544 nm. Survival is shown in FIG.

Emperor Concentration Pancreatic cancer cell survival rate (average) Standard Deviation 0 μg / ml 1,000 0.000 3.125 μg / ml 0.990 0.066 6.25 μg / ml 0.858 0.056 12.5 μg / ml 0.827 0.066 25 μg / ml 0.790 0.021 50 [mu] g / ml 0.695 0.022 100 μg / ml 0.398 0.015

As a result, as shown in Table 1 and Figure 1, the higher the concentration of the treatment of pancreas, the growth of pancreatic cancer cells was reduced, from which it can be seen that the pancreas has a pancreatic cancer treatment effect. Ie 1.0% at 3.125 μg / ml, 14.2% at 6.25 μg / ml, 17.3% at 12.5 μg / ml, 21.0% at 25 μg / ml, 30.5% at 50 μg / ml, 60.2% at 100 μg / ml Pancreatic cancer cells were killed. In addition, the IC ₅₀ (half maximal inhibitory concentration) was determined to be 83.0 μg / ml. Table 1 describes the relative cell numbers of pancreatic cancer cells after 48 hours according to the concentration of each pancreas based on the number of survival rates of pancreatic cancer cells of the control group not treated with cheonyan lotus. As such, the extract of Cheonhwang lotus of the present invention has excellent Panc-1 cell killing activity and further demonstrates pancreatic cancer treatment and prophylactic activity.

Example 3 Acute Toxicity Test by Cheonhwang Lyeon Extract

Cheonhwang lotus used in the present invention was widely used as a medicinal herb, but it was determined that there is no problem in stability, but the oral administration and intraperitoneal toxicity experiments were carried out to confirm this.

Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in suspension of the extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemistry test, autopsy findings, etc. As a result, all of the extracts of Chun-hwang did not show toxic changes up to 5 g / kg in rats, and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of 5 g / kg or more.

Preparation Example 1 Preparation of Pancreatic Cancer Therapeutic Agents Containing Cheonhwang Lyeon Extract as an Active Ingredient

The inventors have confirmed that the pancreatic cancer treatment effect of the cheonyan lotus extract is excellent through the above embodiment to prepare a pancreatic cancer therapeutic agent containing the extract as an active ingredient as follows. In addition, the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.

<1-1> Soft gelatin capsules (wt%) containing cheonyan lotus extract

Cheonhwang Lotus Extract 20%

Vitamin C 4.5%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

10% wax

Palm oil 25%

Safflower Seed Oil 30.399%

 <1-2> Preparation of Intravenous Formulation Containing Cheonhwang Lyeon Extract (% by weight)

Cheonhwang Lotus Extract 0.2%

Mannitol 0.3%

Saline 9.5%

<1-3> tablet (wt%) containing the cheonyan lotus extract

Cheonhwang Lotus Extract 35%

Vitamin C 10%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

Crystalline cellulose 25.0%

Lactose 17.999%

Magnesium Stearate 2%

Preparation Example 2 Preparation of Cosmetic Composition Containing Cheonhwang Lyeon Extract as an Active Ingredient

The present inventors have confirmed that the cheonhwang lotus extract has excellent pancreatic cancer treatment activity through the above embodiment to prepare a cosmetic composition containing it as an active ingredient as follows.

<2-1> Nutritional Cosmetic Water Containing Cheonhwang Lotus Extract (wt%)

Nutrients were prepared in a conventional manner according to the composition described below.

Glycerin 8.0%

Butylene Glycol 4.0%

Hyaluronic Acid Extract 5.0%

Beta Glucan 7.0%

Carbomer 0.1%

Cheonyan lotus extract 0.05%

Capric and Capric Triglycerides 8.0%

Squalane 5.0%

Cetearyl Glucoside 1.5%

Sorbitan stearate 0.4%

Cetearyl Alcohol 1.0%

Triethanol Amine 0.1%

Purified water level

<2-2> Nutritional Cream Containing Cheonhwang Lotus Extract (wt%)

The nourishing cream was prepared by a conventional method according to the composition described below.

Glycerin 3.0%

Butylene Glycol 3.0%

Liquid paraffin 7.0%

Beta Glucan 7.0%

Carbomer 0.1%

Cheonyan lotus extract 3.0%

Capric & Capric Triglycerides 3.0%

Squalane 5.0%

Cetearyl Glucoside 1.5%

Sorbitan stearate 0.4%

Polysorbate 60 1.2%

Triethanol Amine 0.1%

Purified water level

<2-3> Massage cream containing cheonyan lotus extract (% by weight)

Massage creams were prepared in a conventional manner according to the composition described below.

Glycerin 8.0%

Butylene Glycol 4.0%

Liquid paraffin 45.0%

Beta Glucan 7.0%

Carbomer 0.1%

Cheonyan lotus extract 1.0%

Capric & Capric Triglycerides 3.0%

Beeswax 4.0%

Cetearyl Glucoside 1.5%

Sesqui oleic acid sorbitan 0.9%

Vaseline 3.0%

Paraffin 1.5%

Purified water level

<2-4> Pack containing the cheonyan lotus extract (% by weight)

Packs were prepared by conventional methods according to the compositions described below.

Glycerin 4.0%

Polyvinyl Alcohol 15.0%

Hyaluronic Acid Extract 5.0%

Beta Glucan 7.0%

Allantoin 0.1%

Cheonyan lotus extract 0.5%

Nonyl Phenyl Ether 0.4%

Polysorbate 60 1.2%

Ethanol 6.0%

Purified water level

<2-5> Skin external preparation ointment containing cheonhwang lotus extract (% by weight)

Ointments were prepared in a conventional manner according to the compositions described below.

Glycerin 8.0%

Butylene Glycol 4.0%

Liquid paraffin 15.0%

Beta Glucan 7.0%

Carbomer 0.1%

Cheonyan lotus extract 3.0%

Squalane 1.0%

Cetearyl Glucoside 1.5%

Sorbitan stearate 0.4%

Cetearyl Alcohol 1.0%

Beeswax 4.0%

Purified water level

On the other hand, the specific scope of the present invention is defined by the claims rather than the embodiments described above, all changes and modifications derived from the meaning and scope and equivalent concepts of the claims to the scope of the invention It should be interpreted as including.

Claims (7)

A composition for preventing and treating pancreatic cancer, comprising ethanol extract of Coptidis Rhizoma as an active ingredient.
According to claim 1, wherein the ethanol extract is a composition for preventing and treating pancreatic cancer, characterized in that extracted for 24 hours at 50 ℃.
The pancreatic cancer prevention and treatment composition according to claim 1 or 2, wherein the ethanol extract is dried and concentrated under a reduced pressure of 45 ° C.
According to claim 1 or 2, wherein the ethanol is a composition for the prevention and treatment of pancreatic cancer, characterized in that 95%.
The composition for preventing and treating pancreatic cancer according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
According to claim 1, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) composition for the prevention and treatment of pancreatic cancer.
A cosmetic composition for preventing pancreatic cancer comprising ethanol extract of Coptidis Rhizoma containing a cosmetically acceptable cosmetic auxiliary additive as an active ingredient.

Images